A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Claritin D Overdose, Contraindications and Information - Loratadine and Pseudoephedrine
Claritin D Overdose, Contraindications and Information - Loratadine and Pseudoephedrine
OVERDOSE
In the event of overdosage, general symptomatic
and supportive measures should be instituted promptly and maintained
for as long as necessary. Treatment of overdosage would reasonably
consist of emesis (ipecac
syrup), except in patients with impaired consciousness, followed
by the administration
of activated charcoal
to absorb any remaining
drug. If vomiting is
unsuccessful, or contraindicated, gastric
lavage should be performed
with normal saline. Saline
cathartics may also be of value
for rapid dilution
of bowel contents. Loratadine
is not eliminated by hemodialysis. It is not known if loratadine
is eliminated by peritoneal
dialysis.
Somnolence, tachycardia, and headache
have been reported with doses of 40 to 180 mg
of loratadine; pseudoephedrine. In
large doses, sympathomimetics may give rise to giddiness, headache,
nausea, vomiting, sweating, thirst, tachycardia, precordial
pain, palpitations, difficulty in micturition, muscular weakness
and tenseness, anxiety, restlessness, and insomnia. Many patients
can present a toxic
psychosis with delusions
and hallucinations. Some may develop cardiac
arrhythmias, circulatory collapse, convulsions, coma, and respiratory
failure.
The oral median
lethal dose
for the mixture of the
two drugs was greater than 525 and 1839 mg/kg in mice and rats,
respectively (approximately 10 and 58 times the maximum
recommended human daily
oral loratadine; pseudoephedrine
sulfate 24 hour dose
on a mg/m2 basis). The oral median lethal
dose for loratadine
was greater than 5000 mg/kg in rats and mice (greater than 2000
times the maximum recommended
human daily oral
loratadine; pseudoephedrine sulfate
24 hourdose on a mg/m2 basis). Single oral
doses of loratadine
showed no effects in rats, mice, and monkeys at doses as high as
10 times the maximum
recommended human daily
oral dose
on a mg/m2 basis.
CONTRAINDICATIONS
Loratadine; pseudoephedrine sulfate
extended release tablets
are contraindicated in patients who are hypersensitive
to this medication
or to any of its ingredients.
This product, due to its pseudoephedrine component, is contraindicated
in patients with narrow-angle glaucoma
or urinary retention, and in patients receiving monoamine
oxidase (MAO) inhibitor
therapy or within fourteen (14) days of stopping such treatment
(see DRUG INTERACTIONS). It
is also contraindicated in patients with severe hypertension, severe
coronary artery disease, and in those who have shown hypersensitivity
or idiosyncrasy to its components, to adrenergic
agents, or to other drugs of similar chemical
structures. Manifestations of patient idiosyncrasy to adrenergic
agents include: insomnia, dizziness, weakness, tremor, or arrhythmias.
top
